keyword
MENU ▼
Read by QxMD icon Read
search

Aprepitant

keyword
https://www.readbyqxmd.com/read/28919769/evaluating-the-antiemetic-administration-consistency-to-prevent-chemotherapy-induced-nausea-and-vomiting-with-the-standard-guidelines-a-prospective-observational-study
#1
Afsaneh Vazin, Davood Eslami, Ebrahim Sahebi
Nausea and vomiting (NV) are the most prevalent adverse effects of chemotherapy (CT). This study was conducted to evaluate adherence of the health care team to standard guidelines for antiemetics usage to prevent acute chemotherapy-induced nausea and vomiting (CINV) in a large CT center. A prospective study was performed during an 11-month period on patients receiving CT. A form was designed to collect patients' demographic information and their chemotherapeutic and antiemetic regimen data. The Likert scale was used to measure the effectiveness of the antiemetics in patients...
2017: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/28919712/recent-developments-in-the-clinical-pharmacology-of-rolapitant-subanalyses-in-specific-populations
#2
REVIEW
Bernardo Leon Rapoport, Matti Aapro, Martin R Chasen, Karin Jordan, Rudolph M Navari, Ian Schnadig, Lee Schwartzberg
Knowledge of the involvement of the neurokinin substance P in emesis has led to the development of the neurokinin-1 receptor antagonists (NK-1 RAs) for control of chemotherapy-induced nausea and vomiting (CINV), in combination with serotonin type 3 receptor antagonists and corticosteroids. The NK-1 RA rolapitant, recently approved in oral formulation, has nanomolar affinity for the NK-1 receptor, as do the other commercially available NK-1 RAs, aprepitant and netupitant. Rolapitant is rapidly absorbed and has a long half-life in comparison to aprepitant and netupitant...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28867732/comparison-between-antiemetic-effects-of-palonosetron-and-granisetron-on-chemotherapy-induced-nausea-and-vomiting-in-japanese-patients-treated-with-r-chop
#3
Mayako Uchida, Yasuo Mori, Tsutomu Nakamura, Koji Kato, Kenjiro Kamezaki, Katsuto Takenaka, Motoaki Shiratsuchi, Kaori Kadoyama, Toshihiro Miyamoto, Koichi Akashi
In the present study, the antiemetic effect of palonosetron, not combined with dexamethasone and aprepitant, on chemotherapy-induced nausea and vomiting was evaluated in patients with malignant lymphoma receiving first-line rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy, and was compared to that of granisetron. A total of 74 patients with non-Hodgkin lymphoma were included in this study (April 2007 to December 2015). Palonosetron (0.75 mg) or granisetron (3 mg) was intravenously administered before R-CHOP therapy...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28856448/olanzapine-for-prevention-of-chemotherapy-induced-nausea-and-vomiting-in-children-and-adolescents-a-multi-center-feasibility-study
#4
J Flank, T Schechter, P Gibson, D L Johnston, A D Orsey, C Portwine, L Sung, L L Dupuis
CONTEXT: There are no prospective pediatric trials evaluating olanzapine for chemotherapy-induced nausea and vomiting (CINV) prevention. OBJECTIVE: This study evaluated the feasibility of a trial of olanzapine to evaluate the contribution of olanzapine to CINV control in pediatric oncology patients. METHODS: Patients < 18 years receiving CINV prophylaxis with ondansetron/granisetron/palonosetron ± dexamethasone ± aprepitant were eligible to participate in this prospective, single-arm, open-label study...
August 30, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28855996/comparative-investigation-of-the-anti-emetic-effects-of-granisetron-and-palonosetron-during-the-treatment-of-acute-myeloid-leukemia
#5
Aki Matsumaru, Yutaka Tsutsumi, Shinichi Ito
Chemotherapy-induced nausea and vomiting has a considerable negative impact on the quality of life of patients with cancer. Unfortunately, there has been little progress in the development of supportive therapies for the anti-emetic treatment of patients with hematopoietic tumors. This lack of supportive treatments motivated the present retrospective comparison between two groups of anti-emetic drugs. The current study aimed to compare granisetron and palonosetron in order to determine which is more effective, based on cases of patients undergoing remission induction therapy and consolidation therapy for the treatment of acute myeloid leukemia...
October 2017: Molecular and Clinical Oncology
https://www.readbyqxmd.com/read/28853492/role-of-substance-p-and-its-receptor-neurokinin-1-in-chronic-prurigo-a-randomized-proof-of-concept-controlled-trial-with-topical-aprepitant
#6
Tatevik Ohanyan, Nicole Schoepke, Stefan Eirefelt, Gert Hoey, Witte Koopmann, Tomasz Hawro, Marcus Maurer, Martin Metz
Substance P (SP) and its receptor neurokinin 1 (NK1R) are thought to be involved in the pathogenesis of chronic prurigo. Here, we assessed SP serum levels, cutaneous NK1R expression, and the effects of topical aprepitant, an NK1R antagonist, in patients with chronic prurigo. SP and NK1R were increased, compared with controls, in the serum and in lesional vs. non-lesional skin of the patients, respectively. Aprepitant, in a randomized, placebo-controlled, split-sided, double-blind trial, reduced the intensity of pruritus as assessed by visual analogue scale by > 50% from baseline to day 28 (-35...
August 30, 2017: Acta Dermato-venereologica
https://www.readbyqxmd.com/read/28851540/mast-cell-inhibition-as-a-therapeutic-approach-in-fibrodysplasia-ossificans-progressiva-fop
#7
Tracy A Brennan, Carter M Lindborg, Christian R Bergbauer, Haitao Wang, Frederick S Kaplan, Robert J Pignolo
BACKGROUND: Episodic flare-ups of fibrodysplasia ossificans progressiva (FOP) are characterized clinically by severe, often posttraumatic, connective tissue swelling and intramuscular edema, followed histologically by an intense and highly angiogenic fibroproliferative reaction. This early inflammatory and angiogenic fibroproliferative response is accompanied by the presence of abundant mast cells far in excess of other reported myopathies. RESULTS: Using an injury-induced, constitutively-active transgenic mouse model of FOP we show that mast cell inhibition by cromolyn, but not aprepitant, results in a dramatic reduction of heterotopic ossification...
August 26, 2017: Bone
https://www.readbyqxmd.com/read/28844591/addition-of-3-day-aprepitant-to-ondansetron-and-dexamethasone-for-prophylaxis-of-chemotherapy-induced-nausea-and-vomiting-among-patients-with-diffuse-large-b-cell-lymphoma-receiving-5-day-cisplatin-based-chemotherapy
#8
Raafat Abdel-Malek, Noha Abbas, Kyrillus S Shohdy, Mohamed Ismail, Radwa Fawzy, Dalal S Salem, Ezzat Safwat
BACKGROUND: Neurokinin-1 receptor antagonists, such as aprepitant are currently emerging as powerful prophylactic agents for chemotherapy-induced nausea and vomiting (CINV). Therefore, it is important to adjust the anti-emetic regimens based on personal risk factors of the patient, duration of the chemotherapy regimen and cost-effectiveness. PURPOSE: To determine the efficacy of the 3-day aprepitant along with ondansetron and dexamethasone in controlling CINV in patients with large B cell lymphoma receiving multiday-cisplatin regimen chemotherapy...
August 22, 2017: Journal of the Egyptian National Cancer Institute
https://www.readbyqxmd.com/read/28814387/effects-of-nk1-receptors-on-gastric-motor-functions-and-satiation-in-healthy-humans-results-from-a-controlled-trial-with-the-nk1-antagonist-aprepitant
#9
Deepti Jacob, Irene A Busciglio, Duane D Burton, Houssam Halawi, Ibironke Oduyebo, Deborah Rhoten, Michael Ryks, W Scott Harmsen, Michael Camilleri
Aprepitant, an NK1 receptor antagonist, is approved for the treatment of chemotherapy-induced or postoperative emesis by blocking NK1 receptors in the brain stem vomiting center. Effects of NK1 receptors on gastric functions and postprandial symptoms in humans are unclear; a single, crossover study did not show a significant effect of aprepitant on gastrointestinal transit. Our aim was to compare, in a randomized, double-blind, placebo-controlled, parallel-group study (12 healthy volunteers per group), effects of aprepitant vs...
August 16, 2017: American Journal of Physiology. Gastrointestinal and Liver Physiology
https://www.readbyqxmd.com/read/28790262/-determination-of-the-effect-of-aprepitant-and-fosaprepitant-for-nausea-in-patients-with-oral-cancer-receiving-combination-chemotherapy-with-tpf
#10
Kimio Uchiyama, Manabu Yamada, Yuusuke Shiiba, Shingo Kasazaki, Kenichirou Suga, Hiroshi Iwabuchi, Seiji Asoda, Keita Uehara
The objective of this study was to determine the effect of aprepitant(from days 1 to 3, po)and fosaprepitant(day 1, iv) for nausea in patients with oral cancer receiving combination chemotherapy with docetaxel, nedaplatin, or cisplatin(divided doses for 5 days), and 5-fluorouracil(TPF).The incidence rate of nausea in the aprepitant group was 60%(6/10), and that in the fosaprepitant group was 90%(9/10).The incidence rate of continuous nausea for more than 2 days was significantly lower in the aprepitant group than in the fosaprepitant group(40%[4/10]vs 90%[9/10], p=0...
July 2017: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/28765126/cost-utility-and-budget-impact-analyses-of-the-use-of-nepa-for-chemotherapy-induced-nausea-and-vomiting-prophylaxis-in-italy
#11
Umberto Restelli, Gabriella Saibene, Patrizia Nardulli, Roberta Di Turi, Erminio Bonizzoni, Francesca Scolari, Tania Perrone, Davide Croce, Luigi Celio
OBJECTIVE: To evaluate the efficiency of resources allocation and sustainability of the use of netupitant+palonosetron (NEPA) for chemotherapy-induced nausea and vomiting (CINV) prophylaxis assuming the Italian National Health Service (NHS) perspective. A published Markov model was adapted to assess the incremental cost-utility ratio of NEPA compared with aprepitant (APR) + palonosetron (PALO), fosaprepitant (fAPR) + PALO, APR + ondansetron (ONDA), fAPR + ONDA in patients receiving a highly emetogenic chemotherapy (HEC) and with APR + PALO and fAPR + PALO in patients receiving a moderately emetogenic chemotherapy (MEC)...
August 1, 2017: BMJ Open
https://www.readbyqxmd.com/read/28753469/nk1-receptor-antagonists-for-depression-why-a-validated-concept-was-abandoned
#12
REVIEW
Nadia M J Rupniak, Mark S Kramer
BACKGROUND: NK1 receptor antagonists were abandoned despite antidepressant efficacy in five randomized clinical trials. The loss of confidence may be attributed to the failure of a Phase III clinical program with the NK1 receptor antagonist aprepitant in Major Depression. This review examines how PET receptor occupancy was used to select doses for aprepitant and that these may not have achieved adequate exposure. METHODS: PubMed, Google Scholar, and FDA databases were searched for articles concerning NK1 receptor antagonists, human PET receptor occupancy and clinical trials in Major Depression...
July 20, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28749696/influence-of-physiological-gastrointestinal-surfactant-ratio-on-the-equilibrium-solubility-of-bcs-class-ii-drugs-investigated-using-a-four-component-mixture-design
#13
Zhou Zhou, Claire Dunn, Ibrahim Khadra, Clive G Wilson, Gavin W Halbert
The absorption of poorly water-soluble drugs is influenced by the luminal gastrointestinal fluid content and composition, which control solubility. Simulated intestinal fluids have been introduced into dissolution testing including endogenous amphiphiles and digested lipids at physiological levels; however, in vivo individual variation exists in the concentrations of these components, which will alter drug absorption through an effect on solubility. The use of a factorial design of experiment and varying media by introducing different levels of bile, lecithin, and digested lipids has been previously reported, but here we investigate the solubility variation of poorly soluble drugs through more complex biorelevant amphiphile interactions...
August 22, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28737398/in-vivo-mechanisms-of-intestinal-drug-absorption-from-aprepitant-nanoformulations
#14
Carl Roos, David Dahlgren, Staffan Berg, Jan Westergren, Bertil Abrahamsson, Christer Tannergren, Erik Sjögren, Hans Lennernäs
Over recent decades there has been an increase in the proportion of BCS class II and IV drug candidates in industrial drug development. To overcome the biopharmaceutical challenges associated with the less favorable properties of solubility and/or intestinal permeation of these substances, the development of formulations containing nanosuspensions of the drugs has been suggested. The intestinal absorption of aprepitant from two nanosuspensions (20 μM and 200 μM total concentrations) in phosphate buffer, one nanosuspension (200 μM) in fasted-state simulated intestinal fluid (FaSSIF), and one solution (20 μM) in FaSSIF was investigated in the rat single-pass intestinal perfusion model...
August 10, 2017: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/28735677/genetic-risk-factors-associated-with-antiemetic-efficacy-of-palonosetron-aprepitant-and-dexamethasone-in-japanese-breast-cancer-patients-treated-with-anthracycline-based-chemotherapy
#15
Satoshi Yokoyama, Satoshi Tamaru, Shinya Tamaki, Daisuke Nakanishi, Akiya Mori, Tomokazu Yamakawa, Takaaki Ao, Yasuhiko Sakata, Toshiro Mizuno, Takuya Iwamoto, Kenichi Watanabe, Makoto Simomura, Keiki Kawakami, Naomi Konishi, Shinichi Kageyama, Shoichiro Ohtani, Tomomi Yamada, Susumu Ban, Kazuya Ooi
INTRODUCTION: Breast cancer patients often receive anthracycline-based chemotherapy, and chemotherapy-induced nausea and vomiting (CINV) remains one of the most uncomfortable and distressing adverse reactions. Poor control of CINV reduces the relative dose intensity of chemotherapy agents, which has been associated with poor clinical outcomes and shorter survival. The aim of the present study was to identify genetic risk factors associated with anthracycline-based CINV. PATIENTS AND METHODS: We evaluated CINV attributable to anthracycline-based chemotherapy in Japanese breast cancer patients treated with an antiemetic regimen that included palonosetron, aprepitant, and dexamethasone...
June 29, 2017: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28733700/feasibility-of-olanzapine-multi-acting-receptor-targeted-antipsychotic-agent-for-the-prevention-of-emesis-caused-by-continuous-cisplatin-or-ifosfamide-based-chemotherapy
#16
Seiko Bun, Kan Yonemori, Toru Akagi, Emi Noguchi, Tatsunori Shimoi, Akihiko Shimomura, Mayu Yunokawa, Chikako Shimizu, Yasuhiro Fujiwara, Yoshinori Makino, Yoshikazu Hayashi, Kenji Tamura
Background To determine the feasibility and efficacy of olanzapine, which is approved by the Pharmaceuticals and Medical Devices Agency as multi acting receptor targeted antipsychotic agent of the thienobenzodiazepine class, for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients undergoing continuous five-day chemotherapy. Patients and methods This study was a prospective dose escalation study at a single center (UMIN ID: UMIN000015386). Patients received a combination of adriamycin and ifosfamide (AI) or a combination of bleomycin, etoposide, and cisplatin (BEP)...
July 21, 2017: Investigational New Drugs
https://www.readbyqxmd.com/read/28694084/olanzapine-reduces-chemotherapy-induced-nausea-and-vomiting-compared-with-aprepitant-in-myeloma-patients-receiving-high-dose-melphalan-before-stem-cell-transplantation-a-retrospective-study
#17
Steven Trifilio, Colleen Welles, Kristin Seeger, Shivani Mehta, MaryAnne Fishman, Katherine McGowan, Kathryn Strejcek, Emily Eiten, Carolyn Pirotte, Elizabeth Lucier, Sean DeFrates, Jayesh Mehta
INTRODUCTION: Acute and delayed chemotherapy-induced nausea and vomiting (CINV) occurs in most patients who receive high-dose melphalan and significantly affects patients' quality of life during autologous stem cell transplantation. Faced with unsatisfactory results using an aprepitant-based regimen, an olanzapine-based regimen was initiated, with the hope of improving the incidence of acute and delayed CINV. A retrospective study was conducted to compare the effectiveness of olanzapine- versus aprepitant-based regimens for CINV prevention in adult hematopoietic stem cell recipients who received high-dose melphalan...
June 20, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28691209/efficacy-of-the-oral-neurokinin-1-receptor-antagonist-aprepitant-for-nausea-and-vomiting-induced-by-cisplatin-and-carboplatin-in-japanese-patients-with-gynecological-cancer
#18
Masae Ikeda, Masako Shida, Takeshi Hirasawa, Toshinari Muramatsu, Mikio Mikami
AIM: This study was conducted to evaluate the efficacy and the difference in effects of the oral neurokinin-1(NK-1) receptor antagonist aprepitant for chemotherapy-induced nausea/vomiting (CINV) in Japanese patients with gynecological cancer receiving highly emetogenic (cisplatin) and moderately emetogenic (carboplatin) chemotherapy. METHODS: Aprepitant was added during the second course of chemotherapy in Japanese patients with grade ≥ 2 (Common Terminology Criteria for Adverse Events, version 3...
July 10, 2017: Journal of Obstetrics and Gynaecology Research
https://www.readbyqxmd.com/read/28674839/the-role-of-aprepitant-in-prevention-of-postoperative-nausea-and-vomiting-after-bariatric-surgery
#19
Isaac W Therneau, Erin E Martin, Juraj Sprung, Todd A Kellogg, Darrell R Schroeder, Toby N Weingarten
BACKGROUND: Postoperative nausea and vomiting (PONV) is common with bariatric surgery. We examined the PONV rate in bariatric surgical patients who received triple antiemetic prophylaxis (dexamethasone, droperidol, and ondansetron) with and without antiemetic aprepitant. METHODS: Medical records of female patients undergoing laparoscopic bariatric surgery from January 1, 2014, to July 28, 2016, were reviewed for PONV episodes during 48 postoperative hours. RESULTS: In total, 338 patients received triple antiemetic, of whom 172 (51%) also received aprepitant...
July 3, 2017: Obesity Surgery
https://www.readbyqxmd.com/read/28638451/antiemetic-effectiveness-and-cost-saving-of-aprepitant-plus-granisetron-is-superior-to-palonosetron-in-gastrointestinal-cancer-patients-who-received-moderately-emetogenic-chemotherapy
#20
Haruka Toda, Hitoshi Kawazoe, Akiko Yano, Yuji Yamamoto, Yuji Watanabe, Yasunori Yamamoto, Yoichi Hiasa, Yoshihiro Yakushijin, Akihiro Tanaka, Hiroaki Araki
Purpose The therapeutic benefit of a three-drug combination of antiemetics has not been established in moderately emetogenic chemotherapy (MEC). The aim of this study was to compare the antiemetic effectiveness and cost-saving of palonosetron plus dexamethasone (control group) with aprepitant, granisetron, and dexamethasone (study group) in cancer patients who received MEC. Methods We switched the standard antiemetic treatment from the control group to the study group in gastrointestinal cancer patients who received MEC after October 2015...
2017: Journal of Cancer
keyword
keyword
84690
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"